HB-adMSCs ( DrugBank: HB-adMSCs )


7 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症1
4原発性側索硬化症1
6パーキンソン病4
13多発性硬化症/視神経脊髄炎1
46悪性関節リウマチ1
49全身性エリテマトーデス1
113筋ジストロフィー1

2. 筋萎縮性側索硬化症


臨床試験数 : 624 薬物数 : 623 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04514952
(ClinicalTrials.gov)
October 20, 202012/8/2020Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral SclerosisIndividual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisBiological: HB-adMSCsHope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availableN/AN/AAllUnited States

4. 原発性側索硬化症


臨床試験数 : 7 薬物数 : 17 - (DrugBank : 9) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 32
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04825613
(ClinicalTrials.gov)
June 1, 202125/3/2021Individual Patient Expanded Access IND to Treat Primary Lateral SclerosisIndividual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Primary Lateral SclerosisPrimary Lateral Sclerosis, Adult, 1Biological: HB-adMSCsHope Biosciences Stem Cell Research FoundationHope BiosciencesTemporarily not available18 YearsN/AMaleUnited States

6. パーキンソン病


臨床試験数 : 2,298 薬物数 : 2,218 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04995081
(ClinicalTrials.gov)
July 16, 202116/7/2021Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate) (PD)A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's DiseaseParkinson DiseaseBiological: Biological/Vaccine: Allogeneic HB-adMSCs;Other: PlaceboHope Biosciences Stem Cell Research FoundationHope BiosciencesRecruiting45 Years80 YearsAll60Phase 2United States
2NCT04772378
(ClinicalTrials.gov)
July 14, 202123/2/2021Individual Patient Expanded Access IND of HB-adMSCs for the Treatment of Parkinson's DiseaseIndividual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Parkinson's DiseaseParkinson DiseaseBiological: HB-adMSCsHope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer available18 YearsN/AMaleUnited States
3NCT04928287
(ClinicalTrials.gov)
June 28, 202126/5/2021Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's DiseaseParkinson DiseaseBiological: HB-adMSCs;Other: PlaceboHope Biosciences Stem Cell Research FoundationHope BiosciencesActive, not recruiting18 Years75 YearsAll24Phase 2United States
4NCT04064983
(ClinicalTrials.gov)
September 14, 201919/8/2019Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's DiseaseIndividual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Parkinson's DiseaseParkinson DiseaseBiological: HB-adMSCsHope BiosciencesNULLNo longer available18 YearsN/AAllUnited States

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,342 薬物数 : 2,380 - (DrugBank : 407) / 標的遺伝子数 : 266 - 標的パスウェイ数 : 240
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05116540
(ClinicalTrials.gov)
November 24, 202127/10/2021Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple SclerosisA Randomized, Double-Blind, Single-Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Multiple SclerosisMultiple SclerosisBiological: HB-adMSCs;Drug: PlaceboHope Biosciences Stem Cell Research FoundationNULLRecruiting18 Years75 YearsAll24Phase 2United States

46. 悪性関節リウマチ


臨床試験数 : 4,325 薬物数 : 2,681 - (DrugBank : 417) / 標的遺伝子数 : 185 - 標的パスウェイ数 : 223
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03691909
(ClinicalTrials.gov)
September 25, 201827/9/2018A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Rheumatoid ArthritisA Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid ArthritisRheumatoid ArthritisBiological: HB-adMSCsHope BiosciencesNULLCompleted18 Years65 YearsAll15Phase 1/Phase 2United States

49. 全身性エリテマトーデス


臨床試験数 : 946 薬物数 : 733 - (DrugBank : 186) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 198
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04907175
(ClinicalTrials.gov)
July 23, 202126/5/2021Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)System; Lupus ErythematosusBiological: HB-adMSCsHope Biosciences Stem Cell Research FoundationHope BiosciencesTemporarily not available18 Years75 YearsFemaleUnited States

113. 筋ジストロフィー


臨床試験数 : 622 薬物数 : 494 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05154851
(ClinicalTrials.gov)
October 1, 20209/12/2021Individual Patient Expanded Access IND for the Treatment of Spinal Cord Injury, and Congenital Muscular Dystrophy.Individual Patient Expanded Access IND for the Treatment of Spinal Cord Injury, and Congenital Muscular Dystrophy.Spinal Cord Injuries;Congenital Muscular Dystrophy Due to Lamin A/C MutationBiological: HB-adMSCsHope Biosciences Stem Cell Research FoundationNULLNo longer availableN/AN/AMaleUnited States